Login to Your Account

Alexion invests $125M in Moderna messenger RNA technology

By Karen Pihl-Carey
Staff Writer

Monday, January 13, 2014
Attracted to Moderna Therapeutics’ messenger RNA (mRNA) technology platform, Alexion Pharmaceuticals Inc. purchased 10 product options to develop and commercialize rare disease treatments. The Cheshire, Conn.-based company paid $100 million up front for the options, in addition to making a $25 million preferred equity investment in Moderna.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription